Form 4 for DNLI Denali Therapeutics Inc.
Accepted 2026-09-09 16:44:33 ET · period of report 2026-09-04 · accession 0002124755-26-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-09 16:44 | 2026-09-04 | DNLI | Chin Peter Scott | Chief Medical Off | S - Sale | $22.29 | -1,654 | 204.5K | -0.8% | -$36.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-04 | S | D | 1,654 | $22.29 | 204,538 | D | — | — | (F1) Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units. (F2) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.28 to $22.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F3) Includes 142,845 Unvested RSU's (F4) Includes 1,790 shares acquired under the ESPP Purchase on June 1, 2026. |